Actuate Therapeutics develops elraglusib, an experimental cancer drug that targets the GSK-3β enzyme in tumors. ACTU reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 18 | HC Wainwright & Co. | Reiterated | Buy | |
| Jul 30 | Rodman & Renshaw | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in ACTU in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACTU is in one of them and how their past ACTU trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACTU in an article yet. Here's the latest on the wider market.
About Actuate Therapeutics
Actuate Therapeutics is a biopharmaceutical company based in Fort Worth, Texas. It is developing elraglusib, an experimental cancer drug designed to block an enzyme that helps tumors survive and grow. The company is testing the drug mainly in pancreatic cancer, and it is also studying pediatric cancers and other tumor types. It is developing both an injectable form and an oral tablet for patients with difficult to treat cancers.
- Headquarters
- Fort Worth, TX